Skip to main content
. 2020 Feb;8(4):90. doi: 10.21037/atm.2019.12.118

Figure 3.

Figure 3

Survival curve by involved lymph node location in upper, middle, and lower thoracic ESCC patients. (A) Survival curve of patients with positive SCLNs and negative SCLNs in the upper thoracic ESCC patients, median survival time was 25.0±3.0 and 40.0±3.6 months, respectively; (B) survival curve of patients with SCLNs metastasis and other lymph node metastasis (except for SCLNs) in the upper thoracic ESCC patients, median survival time was 25.0±3.0 and 30.0±4.6 months, respectively; (C) survival curve of patients with positive SCLNs and negative SCLNs in middle and lower thoracic ESCC patients, median survival time was 20.0±0.4 and 39.0±3.0 months, respectively; (D) survival curve of patients with SCLNs metastasis and other lymph node metastasis (except for SCLNs) in middle and lower thoracic ESCC patients, median survival time was 20.0±0.4 and 34.0±4.9 months, respectively. ESCC, esophageal squamous cancer; SCLN, supraclavicular lymph node.